Intratumoral expression level of epidermal growth factor receptor and cytokeratin 5/6 is significantly associated with nodal and distant metastases in patients with basal-like triple-negative breast carcinoma

American Journal of Clinical Pathology

Volumn 134, Issue 5, 2010, Pages 782-787

  Sutton, Lisa M ^a   Han, Jeong S ^a   Molberg, Kyle H ^a   Sarode, Venetia R ^a   Cao, Dengfeng ^b   Rakheja, Dinesh ^a   Sailors, Joseph ^a   Peng, Yan ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Department of Pathology and Immunology ^*  (United States)

Author keywords

Basal like phenotype; Cytokeratin 5 6; Epidermal growth factor receptor; Intratumoral expression; Metastasis; Triple negative breast carcinoma

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CONTROLLED STUDY; DISTANT METASTASIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TUMOR CLASSIFICATION; TUMOR VOLUME; BASAL CELL CARCINOMA; BREAST TUMOR; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, BASAL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KERATIN-5; KERATIN-6; LYMPHATIC METASTASIS; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 78049496236     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPRMD3ARUO5WPN     Document Type: Article

References (26)

1. Rakha E, Reis-Filho JS. Basal-like breast carcinoma, from expression profiling to routine practice. Arch Pathol Lab Med. 2009;133:860-867.
2. Rakha EA, El-Slayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109:25-32. (Pubitemid 46120191)
3. Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer. 2007;110:876-884.
4. Lund MJ, Trivers KF, Porter PL, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat. 2009;113:357-370.
5. Dawson SJ, Provenzano E, Caldas C. Triple-negative breast cancers: clinical and prognostic implications. Eur J Cancer. 2009;45(suppl 1):27-40.
6. Rhee J, Han S-W, Oh D-Y, et al. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer. 2008;8:307. doi:10.1186/1471-2407-8-307.
7. Bouchalova K, Cizkova M, Cwiertka K, et al. Triple negative breast cancer: current status and prospective targeted treatment based on HER1 (EGFR), TOP2A, and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009;153:13-17.
8. Tang P, Wang J, Bourne P. Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same? Hum Pathol. 2008;39:506-513.
9. Anders C, Carey LA. Understanding and treating triple-negative breast cancer. Oncology (Williston Park). 2008;22:1233-1240, 1243.
10. Tischkowitz M, Brunet J-S, Bégin LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 2007;7:134. doi:10.1186/1471-2407-7-134.
11. Sasa M, Bando Y, Takahashi M, et al. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer. J Surg Oncol. 2008;97:30-34.
12. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
13. Cheang MD, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368-1376.
14. Dogu GG, Ozkan M, Oturk F, et al. Triple-negative breast cancer: immunohistochemical correlation with basaloid markers and prognostic value of survivin. Med Oncol. 2009;27:34-39. doi:10.1007/s12032-009-9166-3.
15. Nofech-Mozes S, Trudeau M, Kahn HK, et al. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. Breast Cancer Res Treat. 2009;118:131-137.
16. Nielson TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-5374.
17. Nogi H, Kobayashi T, Suzuki M, et al. EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer. Oncol Rep. 2009;21:413-417.
18. Tan DS, Marchio C, Jones RL, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat. 2008;111:27-44.
19. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264-271.
20. Viale G, Rotmensz N, Maisonneuve P, et al. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat. 2009;116:317-328.
21. Quintela I, Corte MD, Allende MT, et al. Expression and prognostic value of EGFR in invasive breast cancer. Oncol Rep. 2005;14:1655-1663.
22. Kurebayashi J. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics. Breast Cancer. 2009;16:275-278.
23. Oliveras-Ferraros C, Vazquez-Martin A, Lopez-Bonet E, et al. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer. Int J Oncol. 2008;33:1165-1176.
24. Corkery B, Crown J, Clynes M, et al. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol. 2009;20:862-867.
25. Yan A, Gidley CT, Horton D, et al. Diagnostic utility of mammaglobin and GCDFP-15 in the identification of metastatic breast carcinoma in fluid specimens. Diagn Cytopathol. 2009;37:475-478.
26. Mazoujian G, Pinkus GS, David S, et al. Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast: a marker of apocrine epithelium and breast carcinomas with apocrine features. Am J Pathol. 1983;110:105-112. (Pubitemid 13147256)